Bristol Myers taps Microsoft AI to speed lung cancer detection
Bristol Myers Squibb (NYSE:BMY) has partnered with Microsoft (NASDAQ:MSFT) to deploy artificial intelligence tools aimed at identifying lung cancer in its earliest stages, marking the latest push by a pharmaceutical giant to integrate big tech’s machine learning into clinical care.









